Cargando…

Estrogen Receptor Ligands: A Review (2013–2015)

Estrogen receptors (ERs) are a group of compounds named for their importance in both menstrual and estrous reproductive cycles. They are involved in the regulation of various processes ranging from tissue growth maintenance to reproduction. Their action is mediated through ER nuclear receptors. Two...

Descripción completa

Detalles Bibliográficos
Autores principales: Farzaneh, Shabnam, Zarghi, Afshin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064234/
https://www.ncbi.nlm.nih.gov/pubmed/28117309
http://dx.doi.org/10.3390/scipharm84030409
_version_ 1782460114286936064
author Farzaneh, Shabnam
Zarghi, Afshin
author_facet Farzaneh, Shabnam
Zarghi, Afshin
author_sort Farzaneh, Shabnam
collection PubMed
description Estrogen receptors (ERs) are a group of compounds named for their importance in both menstrual and estrous reproductive cycles. They are involved in the regulation of various processes ranging from tissue growth maintenance to reproduction. Their action is mediated through ER nuclear receptors. Two subtypes of the estrogen receptor, ERα and ERβ, exist and exhibit distinct cellular and tissue distribution patterns. In humans, both receptor subtypes are expressed in many cells and tissues, and they control key physiological functions in various organ systems. Estrogens attract great attention due to their wide applications in female reproductive functions and treatment of some estrogen-dependent cancers and osteoporosis. This paper provides a general review of ER ligands published in international journals patented between 2013 and 2015. The broad physiological profile of estrogens has attracted the attention of many researchers to develop new estrogen ligands as therapeutic molecules for various clinical purposes. After the discovery of the ERβ receptor, subtype-selective ligands could be used to elicit beneficial estrogen-like activities and reduce adverse side effects, based on the different distributions and relative levels of the two ER subtypes in different estrogen target tissues. Therefore, recent literature has focused on selective estrogen ligands as highly promising agents for the treatment of some types of cancer, as well as for cardiovascular, inflammatory, and neurodegenerative diseases. Estrogen receptors are nuclear transcription factors that are involved in the regulation of many complex physiological functions in humans. Selective estrogen ligands are highly promising targets for treatment of some types of cancer, as well as for cardiovascular, inflammatory and neurodegenerative diseases. Extensive structure-activity relationship studies of ER ligands based on small molecules indicate that many different structural scaffolds may provide high-affinity compounds, provided that some basic structural requirements are present.
format Online
Article
Text
id pubmed-5064234
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-50642342016-10-27 Estrogen Receptor Ligands: A Review (2013–2015) Farzaneh, Shabnam Zarghi, Afshin Sci Pharm Review Estrogen receptors (ERs) are a group of compounds named for their importance in both menstrual and estrous reproductive cycles. They are involved in the regulation of various processes ranging from tissue growth maintenance to reproduction. Their action is mediated through ER nuclear receptors. Two subtypes of the estrogen receptor, ERα and ERβ, exist and exhibit distinct cellular and tissue distribution patterns. In humans, both receptor subtypes are expressed in many cells and tissues, and they control key physiological functions in various organ systems. Estrogens attract great attention due to their wide applications in female reproductive functions and treatment of some estrogen-dependent cancers and osteoporosis. This paper provides a general review of ER ligands published in international journals patented between 2013 and 2015. The broad physiological profile of estrogens has attracted the attention of many researchers to develop new estrogen ligands as therapeutic molecules for various clinical purposes. After the discovery of the ERβ receptor, subtype-selective ligands could be used to elicit beneficial estrogen-like activities and reduce adverse side effects, based on the different distributions and relative levels of the two ER subtypes in different estrogen target tissues. Therefore, recent literature has focused on selective estrogen ligands as highly promising agents for the treatment of some types of cancer, as well as for cardiovascular, inflammatory, and neurodegenerative diseases. Estrogen receptors are nuclear transcription factors that are involved in the regulation of many complex physiological functions in humans. Selective estrogen ligands are highly promising targets for treatment of some types of cancer, as well as for cardiovascular, inflammatory and neurodegenerative diseases. Extensive structure-activity relationship studies of ER ligands based on small molecules indicate that many different structural scaffolds may provide high-affinity compounds, provided that some basic structural requirements are present. MDPI 2016-04-13 2016 /pmc/articles/PMC5064234/ /pubmed/28117309 http://dx.doi.org/10.3390/scipharm84030409 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Farzaneh, Shabnam
Zarghi, Afshin
Estrogen Receptor Ligands: A Review (2013–2015)
title Estrogen Receptor Ligands: A Review (2013–2015)
title_full Estrogen Receptor Ligands: A Review (2013–2015)
title_fullStr Estrogen Receptor Ligands: A Review (2013–2015)
title_full_unstemmed Estrogen Receptor Ligands: A Review (2013–2015)
title_short Estrogen Receptor Ligands: A Review (2013–2015)
title_sort estrogen receptor ligands: a review (2013–2015)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064234/
https://www.ncbi.nlm.nih.gov/pubmed/28117309
http://dx.doi.org/10.3390/scipharm84030409
work_keys_str_mv AT farzanehshabnam estrogenreceptorligandsareview20132015
AT zarghiafshin estrogenreceptorligandsareview20132015